Zacks Research Has Bearish Estimate for ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $0.51 per share for the year, down from their prior estimate of $0.68. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals' Q1 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.21 EPS, FY2026 earnings at $0.79 EPS and FY2027 earnings at $1.09 EPS.

A number of other brokerages have also commented on ACAD. Needham & Company LLC raised their price target on ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the company a "buy" rating in a report on Monday, May 19th. HC Wainwright raised their target price on shares of ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the company a "buy" rating in a research note on Monday, May 19th. Royal Bank of Canada reissued an "outperform" rating and set a $26.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, May 19th. Cantor Fitzgerald reissued an "overweight" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Finally, Robert W. Baird raised their price objective on shares of ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the company an "outperform" rating in a research note on Monday, May 19th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, ACADIA Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $26.83.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD traded up $0.50 during trading hours on Friday, hitting $21.97. The stock had a trading volume of 380,670 shares, compared to its average volume of 1,930,528. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $25.23. The firm has a market capitalization of $3.68 billion, a price-to-earnings ratio of 28.17 and a beta of 0.47. The stock's fifty day simple moving average is $16.96 and its 200 day simple moving average is $17.51.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $244.32 million for the quarter, compared to analyst estimates of $239.32 million. During the same period last year, the company earned $0.10 earnings per share. The firm's revenue for the quarter was up 18.7% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 9.0% during the first quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company's stock valued at $252,526,000 after buying an additional 1,255,594 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in ACADIA Pharmaceuticals during the first quarter worth approximately $60,845,000. Fred Alger Management LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 2.0% during the 1st quarter. Fred Alger Management LLC now owns 2,769,828 shares of the biopharmaceutical company's stock worth $46,007,000 after buying an additional 54,899 shares during the period. First Trust Advisors LP boosted its holdings in ACADIA Pharmaceuticals by 27.0% during the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company's stock valued at $49,547,000 after acquiring an additional 574,251 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $40,935,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider James Kihara sold 4,000 shares of ACADIA Pharmaceuticals stock in a transaction on Friday, May 16th. The stock was sold at an average price of $22.50, for a total value of $90,000.00. Following the transaction, the insider now directly owns 20,395 shares in the company, valued at $458,887.50. The trade was a 16.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares in the company, valued at $320,756.85. This represents a 21.85% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,746 shares of company stock worth $428,221. 26.50% of the stock is owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.